Xanodyne Pharmaceuticals, a Newport-based specialty pharmaceutical company, is expanding its sales force to support the launch of its new pain drug, Zipsor.
Xanodyne received Food and Drug Administration (FDA) approval this past June for Zipsor, which is a new treatment option for mild to moderate acute pain in adults. The launch is being supported by an expanded 250-member specialty sales force.
“The launch of Zipsor was a tremendous achievement for Xanodyne,” said Xanodyne Chief Commercial Officer Natasha Giordano. “Within 90 days of receiving FDA approval, we were able to scale up our commercial organization and secure broad distribution at retail pharmacies for the product.”
The company recently completed $50 million in equity financing, led by Longitude Capital with participation from new investors Skandia and Silver Point Capital. The additional financing will be used to support the company’s ongoing development and commercialization strategy. The company recently received approval from the FDA?for another new drug, Lysteda. Lysteda is the first and only oral therapeutic agent indicated specifically for the treatment of women suffering from cyclic heavy menstrual bleeding.